(Q38096980)

28 August 2017

Metabolic Surgery for Type 2 Diabetes in Patients with a BMI of <35 kg/m(2): A Surgeon's Perspective (English)

1 reference

28 August 2017

1 reference

Ricardo Cohen

1

1 reference

PubMed ID

23564465

28 August 2017

Pedro Paulo Caravatto

series ordinal

2

1 reference

PubMed ID

23564465

28 August 2017

Tarissa Petry

series ordinal

3

1 reference

28 August 2017

1 June 2013

1 reference

28 August 2017

1 reference

28 August 2017

23

1 reference

28 August 2017

809-818

1 reference

28 August 2017

6

1 reference

https://scigraph.springernature.com/pub.10.1007/s11695-013-0930-2

28 August 2017

0 references

cites work

Legacy effects from DCCT and UKPDS: what they mean and implications for future diabetes trials

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Type 2 diabetes can be prevented with early pharmacological intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Bariatric surgery and long-term cardiovascular events.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Diabetes remission and reduced cardiovascular risk after gastric bypass in Asian Indians with body mass index <35 kg/m(2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Diabetes remission without weight loss after duodenal bypass surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Metabolic surgery for non-obese type 2 diabetes: incretins, adipocytokines, and insulin secretion/resistance changes in a 1-year interventional clinical controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Laparoscopic treatment of type 2 diabetes mellitus for patients with a body mass index less than 35.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Gastrointestinal surgery as a treatment for diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Is type 2 diabetes an operable intestinal disease? A provocative yet reasonable hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Beyond the BMI: the search for better guidelines for bariatric surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Wrist circumference as a novel predictor of diabetes and prediabetes: results of cross-sectional and 8.8-year follow-up studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Identification and characterization of metabolically benign obesity in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

The metabolically benign and malignant fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Clinical Review: Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

The importance of caloric restriction in the early improvements in insulin sensitivity after Roux-en-Y gastric bypass surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Long-term persistence of hormonal adaptations to weight loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Bariatric surgery: effects on glucose homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Duodenal-jejunal bypass for the treatment of type 2 diabetes in patients with body mass index of 22-34 kg/m2: a report of 2 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Glycemic control after stomach-sparing duodenal-jejunal bypass surgery in diabetic patients with low body mass index.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Remission of type 2 diabetes after gastric bypass and banding: mechanisms and 2 year outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Loss of insulin resistance after Roux-en-Y gastric bypass surgery: a time course study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Acute effects of gastric bypass versus gastric restrictive surgery on beta-cell function and insulinotropic hormones in severely obese patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Gastric bypass and nesidioblastosis--too much of a good thing for islets?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Patients with neuroglycopenia after gastric bypass surgery have exaggerated incretin and insulin secretory responses to a mixed meal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Reversible hyperinsulinemic hypoglycemia after gastric bypass: a consequence of altered nutrient delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Moderate effect of duodenal-jejunal bypass surgery on glucose homeostasis in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Gastric bypass vs sleeve gastrectomy for type 2 diabetes mellitus: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Early improvement in glycemic control after bariatric surgery and its relationships with insulin, GLP-1, and glucagon secretion in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Metabolic surgery for the treatment of type 2 diabetes in patients with BMI <35 kg/m2: an integrative review of early studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

The effect of bilio-pancreatic diversion on type 2 diabetes in patients with BMI <35 kg/m2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

A review of studies comparing three laparoscopic procedures in bariatric surgery: sleeve gastrectomy, Roux-en-Y gastric bypass and adjustable gastric banding

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Sleeve gastrectomy as sole and definitive bariatric procedure: 5-year results for weight loss and ghrelin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Initial results with sleeve gastrectomy for patients with class I obesity (BMI 30-35 kg/m2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Laparoscopic sleeve gastrectomy for diabetes treatment in nonmorbidly obese patients: efficacy and change of insulin secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Bariatric surgery: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Gastric bypass in the treatment of type 2 diabetes in patients with a BMI of 30 to 35 kg/m2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Effect of laparoscopic mini-gastric bypass for type 2 diabetes mellitus: comparison of BMI>35 and <35 kg/m2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Bariatric surgery versus intensive medical therapy in obese patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Effects of biliopanceratic diversion on type 2 diabetes in patients with BMI 25 to 35.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Early improvement of glucose tolerance after ileal transposition in a non-obese type 2 diabetes rat model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Ileal interposition surgery improves glucose and lipid metabolism and delays diabetes onset in the UCD-T2DM rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Ileal interposition improves glucose tolerance in low dose streptozotocin-treated diabetic and euglycemic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Ileal interposition with sleeve gastrectomy for control of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Ileal interposition with sleeve gastrectomy for treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Short-term and mid-term control of type 2 diabetes mellitus by laparoscopic sleeve gastrectomy with ileal interposition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Prospective randomized controlled trial comparing 2 versions of laparoscopic ileal interposition associated with sleeve gastrectomy for patients with type 2 diabetes with BMI 21-34 kg/m(2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Laparoscopic ileal interposition with diverted sleeve gastrectomy for treatment of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Jejunal nutrient sensing is required for duodenal-jejunal bypass surgery to rapidly lower glucose concentrations in uncontrolled diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Duodenal-jejunal bypass surgery does not increase skeletal muscle insulin signal transduction or glucose disposal in Goto-Kakizaki type 2 diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Surgery for nonobese type 2 diabetic patients: an interventional study with duodenal-jejunal exclusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Laparoscopic duodenal-jejunal exclusion in the treatment of type 2 diabetes mellitus in patients with BMI<30 kg/m2 (LBMI).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

A pilot study of the duodenal-jejunal bypass liner in low body mass index type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Efficacy of lifestyle education to prevent type 2 diabetes: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Metabolic effects of bariatric surgery in type 2 diabetic patients with body mass index < 35 kg/m2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Association of an intensive lifestyle intervention with remission of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

A look ahead at the future of diabetes prevention and treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Bariatric surgery: an IDF statement for obese Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

DPP-4 Inhibitors and Combined Treatment in Type 2 Diabetes: Re-evaluation of Clinical Success and Safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

The Past 200 Years in Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Costs and consequences associated with newer medications for glycemic control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

The great debate: medicine or surgery: what is best for the patient with type 2 diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Surgical vs conventional therapy for weight loss treatment of obstructive sleep apnea: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Effect of a multifactorial intervention on mortality in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Cardiovascular events after bariatric surgery in obese subjects with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Surgery decreases long-term mortality, morbidity, and health care use in morbidly obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

The effect of rosiglitazone on novel atherosclerotic risk factors in patients with type 2 diabetes mellitus and hypertension. An open-label observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Pioglitazone and bladder cancer: a propensity score matched cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Pioglitazone in clinical practice: where are we now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

The risk of bladder cancer in korean diabetic subjects treated with pioglitazone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Cohort study of pioglitazone and cancer incidence in patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Metformin-associated lactic acidosis (MALA): case files of the Einstein Medical Center medical toxicology fellowship

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Metformin and its clinical use: new insights for an old drug in clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Risk of Fatal and Nonfatal Lactic Acidosis With Metformin Use in Type 2 Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

The criteria for metformin-associated lactic acidosis: the quality of reporting in a large pharmacovigilance database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Rosiglitazone and pioglitazone. Beware fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

The risk of fractures associated with thiazolidinediones: a self-controlled case-series study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Acute pancreatitis associated with liraglutide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Alterations in gastrointestinal, endocrine, and metabolic processes after bariatric Roux-en-Y gastric bypass surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Surgical treatment of type 2 diabetes: the surgeon perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Baseline data from American Society for Metabolic and Bariatric Surgery-designated Bariatric Surgery Centers of Excellence using the Bariatric Outcomes Longitudinal Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Risk stratification of serious adverse events after gastric bypass in the Bariatric Outcomes Longitudinal Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Bariatric surgery: risks and rewards

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

The ASBS Bariatric Surgery Centers of Excellence program: a blueprint for quality improvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Nutritional deficiencies after bariatric surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Metabolic surgery to treat type 2 diabetes: clinical outcomes and mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Metabolic surgery: not just weight loss surgery anymore.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Bariatric surgery versus conventional medical therapy for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

The Diabetes Surgery Summit consensus conference: recommendations for the evaluation and use of gastrointestinal surgery to treat type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Standards of medical care in diabetes--2013

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

IDF's view of bariatric surgery in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11695-013-0930-2

Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery

21 January 2018

1 reference

12 December 2020

Long-term weight-loss maintenance: a meta-analysis of US studies

1 reference

12 December 2020

Laparoscopic bariatric surgery: new technologies, trends and perspectives.

1 reference

12 December 2020

Effectiveness of the novel anti-diabetes medication exenatide in everyday practice: Comparison with clinical trials

1 reference

12 December 2020

Nutritional deficiencies after bariatric surgery

1 reference

12 December 2020

Finding new treatments for diabetes--how many, how fast... how good?

1 reference

12 December 2020

Effect of blood glucose control after small intestine exclusion surgery in Goto-Kakizaki rat with type 2 diabetes mellitus

1 reference

12 December 2020

Early results of Roux-en-Y gastric by-pass on regulation of diabetes type 2 in patients with BMI above and below 35 kg/m2.

1 reference

12 December 2020

Duodenal-jejunal bypass protects GK rats from {beta}-cell loss and aggravation of hyperglycemia and increases enteroendocrine cells coexpressing GIP and GLP-1

1 reference

12 December 2020

Effect of Laparoscopic Roux-En Y Gastric Bypass on Type 2 Diabetes Mellitus

1 reference

12 December 2020

Bypass of the duodenum improves insulin resistance much more rapidly than sleeve gastrectomy

1 reference

12 December 2020

Weighing in on bariatric surgery: procedure use, readmission rates, and mortality

1 reference

12 December 2020

Laparoscopic Roux-en-Y gastric bypass for BMI < 35 kg/m(2): a tailored approach.

1 reference

12 December 2020

Rosiglitazone and cardiovascular risk

1 reference

12 December 2020

Incretin-based therapy and pancreatitis-what is the risk?

1 reference

12 December 2020

Laparoscopic sleeve gastrectomy with ileal interposition ("neuroendocrine brake")--pilot study of a new operation

1 reference

12 December 2020

Early postoperative outcomes of metabolic surgery to treat diabetes from sites participating in the ASMBS bariatric surgery center of excellence program as reported in the Bariatric Outcomes Longitudinal Database

1 reference

12 December 2020

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies

1 reference

12 December 2020

10.1007/S11695-013-0930-2

Identifiers

DOI

1 reference

28 August 2017

1 reference

PubMed ID

23564465